OMS824: Phase IIa data

A double-blind, placebo-controlled, U.S. Phase IIa trial in 33 patients showed that 2 dose levels of oral OMS824 were well tolerated and demonstrated comparable systemic pharmacokinetics when given alone and in combination with approved antipsychotic agents for 2 weeks. The trial enrolled patients with stable schizophrenia whose antipsychotic medications have been temporarily discontinued or who continue their antipsychotic regimen. ...